Search bioRxiv⌕ Search

Biology subjects

Cherng, X.

Publications and source records attributed to Cherng, X..

1 recordsLinked to original sources

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

immunology↗